Furthermore, we screened 60 human primary CLL cases with different genomic aberrations, and found a significant increase in RXRα expression in CLL cells of patients with 17p and/or 11q deletions and worse prognosis, as compared to those with 13q deletion and better outcome (Fig. 6b, right panel). The gene discussed is RXRA; the disease is B-cell chronic lymphocytic leukemia.